share_log

Deciphera Pharmaceuticals Analyst Ratings

Deciphera Pharmaceuticals Analyst Ratings

Deciphera 制药分析师评级
Benzinga ·  2023/10/31 13:59
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/31/2023 91.72% Stifel $20 → $22 Maintains Buy
10/31/2023 161.44% HC Wainwright & Co. $25 → $30 Maintains Buy
10/31/2023 — JonesTrading Upgrades Hold → Buy
10/30/2023 100.44% Piper Sandler $18 → $23 Upgrades Neutral → Overweight
08/10/2023 117.86% HC Wainwright & Co. → $25 Reiterates Buy → Buy
08/10/2023 74.29% Stifel $14 → $20 Upgrades Hold → Buy
06/05/2023 100.44% JMP Securities → $23 Reiterates → Market Outperform
05/04/2023 100.44% JMP Securities → $23 Reiterates → Market Outperform
03/15/2023 100.44% JMP Securities → $23 Reiterates → Market Outperform
02/08/2023 117.86% HC Wainwright & Co. → $25 Reiterates → Buy
02/08/2023 161.44% SVB Leerink → $30 Reiterates → Outperform
02/07/2023 161.44% SVB Leerink $28 → $30 Maintains Outperform
01/25/2023 161.44% Cowen & Co. $25 → $30 Maintains Outperform
01/06/2023 — JonesTrading Upgrades Sell → Hold
01/04/2023 144.01% SVB Leerink $25 → $28 Maintains Outperform
01/04/2023 -21.57% Barclays $8 → $9 Maintains Underweight
01/04/2023 91.72% Guggenheim → $22 Upgrades Neutral → Buy
09/27/2022 56.86% Stifel $11 → $18 Maintains Hold
09/12/2022 117.86% SVB Leerink $21 → $25 Maintains Outperform
09/12/2022 117.86% HC Wainwright & Co. $20 → $25 Maintains Buy
08/29/2022 117.86% Cowen & Co. → $25 Initiates Coverage On → Outperform
08/05/2022 83.01% SVB Leerink $15 → $21 Maintains Outperform
08/05/2022 74.29% HC Wainwright & Co. $15 → $20 Maintains Buy
08/05/2022 100.44% JMP Securities → $23 Upgrades Market Perform → Market Outperform
02/28/2022 -47.71% Barclays $11 → $6 Downgrades Equal-Weight → Underweight
12/01/2021 30.72% HC Wainwright & Co. $25 → $15 Maintains Buy
11/08/2021 -12.85% Truist Securities $65 → $10 Downgrades Buy → Hold
11/08/2021 4.58% Canaccord Genuity → $12 Downgrades Buy → Hold
11/08/2021 117.86% HC Wainwright & Co. $70 → $25 Maintains Buy
11/08/2021 -4.14% Barclays $50 → $11 Downgrades Overweight → Equal-Weight
11/08/2021 — Stifel Downgrades Buy → Hold
11/05/2021 -12.85% Truist Securities $65 → $10 Downgrades Buy → Hold
11/05/2021 457.73% JMP Securities $70 → $64 Maintains Market Outperform
08/04/2021 510.02% HC Wainwright & Co. $75 → $70 Maintains Buy
05/05/2021 553.59% HC Wainwright & Co. $80 → $75 Maintains Buy
03/31/2021 579.74% Credit Suisse → $78 Initiates Coverage On → Outperform
02/10/2021 510.02% Barclays $85 → $70 Maintains Overweight
02/10/2021 510.02% SVB Leerink → $70 Upgrades Market Perform → Outperform
12/03/2020 553.59% Stifel → $75 Initiates Coverage On → Buy
11/12/2020 510.02% SVB Leerink $58 → $70 Maintains Market Perform
09/14/2020 405.45% SVB Leerink $54 → $58 Maintains Market Perform
08/05/2020 370.59% SVB Leerink $55 → $54 Maintains Market Perform
05/18/2020 693.03% SunTrust Robinson Humphrey $82 → $91 Maintains Buy
05/07/2020 422.88% Nomura $84 → $60 Downgrades Buy → Neutral
05/07/2020 422.88% Nomura $84 → $60 Downgrades Buy → Neutral
05/06/2020 327.02% JP Morgan $50 → $49 Maintains Overweight
05/06/2020 597.17% HC Wainwright & Co. $60 → $80 Reiterates → Buy
04/29/2020 614.6% SunTrust Robinson Humphrey $77 → $82 Maintains Buy
04/29/2020 379.3% SVB Leerink $50 → $55 Maintains Market Perform
03/04/2020 510.02% Barclays → $70 Initiates Coverage On → Overweight
01/22/2020 632.03% Nomura $57 → $84 Maintains Buy
01/13/2020 571.02% SunTrust Robinson Humphrey → $77 Initiates Coverage On → Buy
11/05/2019 370.59% JMP Securities $45 → $54 Maintains Market Outperform
10/29/2019 — SVB Leerink Upgrades Underperform → Market Perform
10/03/2019 422.88% HC Wainwright & Co. → $60 Initiates Coverage On → Buy
09/30/2019 309.59% Jefferies → $47 Initiates Coverage On → Buy
08/14/2019 379.3% Cantor Fitzgerald $43 → $55 Maintains Overweight
08/14/2019 466.45% Canaccord Genuity $50 → $65 Reiterates → Buy
07/18/2019 266.01% Deutsche Bank → $42 Initiates Coverage On → Buy
03/15/2019 335.73% Canaccord Genuity $55 → $50 Maintains Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
2023年10月31日 91.72% Stifel $20→$22 维护 买
2023年10月31日 161.44% HC Wainwright公司 $25→$30 维护 买
2023年10月31日 - Jones Trading 升级 持有→购买
2023年10月30日 100.44% 派珀·桑德勒 $18→$23 升级 中性→超重
2023年08月10日 117.86% HC Wainwright公司 →$25 重申 购买→购买
2023年08月10日 74.29% Stifel $14→$20 升级 持有→购买
06/05/2023 100.44% JMP证券 →$23 重申 →市场跑赢大盘
05/04/2023 100.44% JMP证券 →$23 重申 →市场跑赢大盘
03/15/2023 100.44% JMP证券 →$23 重申 →市场跑赢大盘
02/08/2023 117.86% HC Wainwright公司 →$25 重申 →购买
02/08/2023 161.44% SVB Leerink →$30 重申 →跑赢大盘
02/07/2023 161.44% SVB Leerink $28→$30 维护 跑赢大盘
2023年1月25日 161.44% 考恩公司 $25→$30 维护 跑赢大盘
01/06/2023 - Jones Trading 升级 销售→Hold
01/04/2023 144.01% SVB Leerink $25→$28 维护 跑赢大盘
01/04/2023 -21.57% 巴克莱 $8→$9 维护 体重不足
01/04/2023 91.72% 古根海姆 →$22 升级 中性→购买
09/27/2022 56.86% Stifel $11→$18 维护 保持
09/12/2022 117.86% SVB Leerink $21→$25 维护 跑赢大盘
09/12/2022 117.86% HC Wainwright公司 $20→$25 维护 买
2022年08月29日 117.86% 考恩公司 →$25 开始承保 →跑赢大盘
08/05/2022 83.01% SVB Leerink $15→$21 维护 跑赢大盘
08/05/2022 74.29% HC Wainwright公司 $15→$20 维护 买
08/05/2022 100.44% JMP证券 →$23 升级 市场表现优于→市场表现
02/28/2022 -47.71% 巴克莱 $11→$6 评级下调 等重→减码
12/01/2021 30.72% HC Wainwright公司 $25→$15 维护 买
11/08/2021 -12.85% Truist证券 $65→$10 评级下调 购买→Hold
11/08/2021 4.58% 卡纳科特·格纳奇 →$12 评级下调 购买→Hold
11/08/2021 117.86% HC Wainwright公司 $70→$25 维护 买
11/08/2021 -4.14% 巴克莱 $50→$11 评级下调 超重→等重
11/08/2021 - Stifel 评级下调 购买→Hold
2021年11月05日 -12.85% Truist证券 $65→$10 评级下调 购买→Hold
2021年11月05日 457.73% JMP证券 $70→$64 维护 市场表现强于大盘
08/04/2021 510.02% HC Wainwright公司 $75→$70 维护 买
05/05/2021 553.59% HC Wainwright公司 $80→$75 维护 买
03/31/2021 579.74% 瑞士信贷 →$78 开始承保 →跑赢大盘
02/10/2021 510.02% 巴克莱 $85→$70 维护 超重
02/10/2021 510.02% SVB Leerink →$70 升级 市场表现优于→
12/03/2020 553.59% Stifel →$75 开始承保 →购买
2020年11月12日 510.02% SVB Leerink $58→$70 维护 市场表现
09/14/2020 405.45% SVB Leerink $54→$58 维护 市场表现
08/05/2020 370.59% SVB Leerink $55→$54 维护 市场表现
05/18/2020 693.03% SunTrust Robinson Humphrey $82→$91 维护 买
05/07/2020 422.88% 野村 $84→$60 评级下调 购买→中性
05/07/2020 422.88% 野村 $84→$60 评级下调 购买→中性
05/06/2020 327.02% 摩根大通 $50→$49 维护 超重
05/06/2020 597.17% HC Wainwright公司 $60→$80 重申 →购买
04/29/2020 614.6% SunTrust Robinson Humphrey $77→$82 维护 买
04/29/2020 379.3% SVB Leerink $50→$55 维护 市场表现
03/04/2020 510.02% 巴克莱 →$70 开始承保 →超重
2020/01/22 632.03% 野村 $57→$84 维护 买
2020/01/13 571.02% SunTrust Robinson Humphrey →$77 开始承保 →购买
2019年11月05日 370.59% JMP证券 $45→$54 维护 市场表现强于大盘
2019年10月29日 - SVB Leerink 升级 表现逊于→市场表现
2019年10月03日 422.88% HC Wainwright公司 →$60 开始承保 →购买
2019年09月30日 309.59% 杰富瑞 →$47 开始承保 →购买
2019年08月14日 379.3% 康托·菲茨杰拉德 $43→$55 维护 超重
2019年08月14日 466.45% 卡纳科特·格纳奇 $50→$65 重申 →购买
2019年07月18日 266.01% 德意志银行 →$42 开始承保 →购买
2019年03月15日 335.73% 卡纳科特·格纳奇 $55→$50 维护 买

What is the target price for Deciphera Pharmaceuticals (DCPH)?

Deciphera制药(DCPH)的目标价是多少？

The latest price target for Deciphera Pharmaceuticals (NASDAQ: DCPH) was reported by Stifel on October 31, 2023. The analyst firm set a price target for $22.00 expecting DCPH to rise to within 12 months (a possible 91.72% upside). 17 analyst firms have reported ratings in the last year.

Deciphera Pharmaceuticals（纳斯达克股票代码：DCPH）的最新价格目标由Stifel于2023年10月31日报道。该分析公司将价格目标定为22.00美元，预计DCPH将在12个月内上涨（可能上涨91.72%）。去年有17家分析公司公布了评级。

What is the most recent analyst rating for Deciphera Pharmaceuticals (DCPH)?

Deciphera PharmPharmticals(DCPH)的最新分析师评级是多少？

The latest analyst rating for Deciphera Pharmaceuticals (NASDAQ: DCPH) was provided by Stifel, and Deciphera Pharmaceuticals maintained their buy rating.

对Deciphera制药公司（纳斯达克股票代码：DCPH）的最新分析师评级由Stifel提供，Deciphera制药公司维持其买入评级。

When is the next analyst rating going to be posted or updated for Deciphera Pharmaceuticals (DCPH)?

Deciphera PharmPharmticals(DCPH)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Deciphera Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Deciphera Pharmaceuticals was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.

分析师在做了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Deciphera制药公司的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月做一次，所以你每年应该对每家公司进行4次评级。Deciphera Pharmaceuticals的最后一次评级于2023年10月31日提交，因此您应该期待下一次评级将在2024年10月31日左右提供。

Is the Analyst Rating Deciphera Pharmaceuticals (DCPH) correct?

分析师评级Deciphera PharmPharmticals(DCPH)正确吗？

While ratings are subjective and will change, the latest Deciphera Pharmaceuticals (DCPH) rating was a maintained with a price target of $20.00 to $22.00. The current price Deciphera Pharmaceuticals (DCPH) is trading at is $11.48, which is out of the analyst's predicted range.

虽然评级是主观的，会发生变化，但最新的Deciphera Pharmaceuticals（DCPH）评级维持在20.00美元至22.00美元的目标价格。Deciphera Pharmaceuticals（DCPH）目前的交易价格为11.48美元，超出了分析师的预测范围。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发